(NASDAQ: DRTS) Alpha Tau Medical's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 112.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23%.
Alpha Tau Medical's revenue in 2026 is $0.On average, 6 Wall Street analysts forecast DRTS's revenue for 2026 to be $138,790,501, with the lowest DRTS revenue forecast at $0, and the highest DRTS revenue forecast at $285,745,149. On average, 5 Wall Street analysts forecast DRTS's revenue for 2027 to be $1,603,574,560, with the lowest DRTS revenue forecast at $915,064,821, and the highest DRTS revenue forecast at $2,848,521,951.
In 2028, DRTS is forecast to generate $6,956,023,419 in revenue, with the lowest revenue forecast at $6,683,204,837 and the highest revenue forecast at $7,160,637,356.